UXIN stock surged by 12.5% at the last trading close while the UXIN stock price kept on rising by 17.95% in the pre-market trading session after
Aptinyx Inc [NASDAQ: APTX] Clinical-stage biopharmaceutical company Aptinyx Inc., reported today of its positive results from the second phase of its novel NVDA receptor module,
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.